SLITRK4抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: PC3 cells, Primary antibody: P01811(SLITRK4 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01811(SLITRK4 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SLITRK4 antibody is a research tool designed to target the SLIT and NTRK-like family member 4 (SLITRK4), a transmembrane protein predominantly expressed in the central nervous system. Belonging to the SLITRK family, SLITRK4 shares structural features such as leucine-rich repeats (LRRs) and a conserved C-terminal domain, which facilitate its role in neurite outgrowth, synaptic modulation, and neural circuit development. Studies link SLITRK4 to psychiatric and neurodegenerative disorders, including schizophrenia, bipolar disorder, and Alzheimer’s disease, due to its influence on synaptic plasticity and neurotransmitter signaling.

This antibody is widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to map SLITRK4 expression patterns, investigate its interactions with postsynaptic receptors (e.g., GABA receptors), and explore its pathological role in disease models. Recent research also implicates SLITRK4 in cancer biology, particularly glioblastoma, where its aberrant expression may correlate with tumor progression. By enabling precise detection and functional analysis, the SLITRK4 antibody serves as a critical reagent for unraveling molecular mechanisms in neurodevelopment, neurodegeneration, and oncology, offering potential insights for therapeutic targeting. Its validation in species-specific and application-specific contexts ensures reliability across experimental platforms.